1103500-20-4

Basic information

• Product Name: TERN-101
• Synonyms: TERN-101
• CAS NO: 1103500-20-4
• Molecular Weight: 540.446
• Mol File: 1103500-20-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 740.1±60.0 °C(Predicted)
• Density: 1.48±0.1 g/cm3(Predicted)
• CAS DataBase Reference: TERN-101(CAS DataBase Reference)
• NIST Chemistry Reference: TERN-101(1103500-20-4)
• EPA Substance Registry System: TERN-101(1103500-20-4)

Safety Data

• Hazardous Substances Data: 1103500-20-4(Hazardous Substances Data)

Usage

Description

LY2562175 is a farnesoid X receptor (FXR) agonist (EC50 = 193 nM in a reporter assay). It is selective for FXR over the glucocorticoid, androgen, mineralocorticoid, and progesterone receptors in HEK293 cells overexpressing the human receptors (EC50s = >10 μM for all in a radioligand binding assay). LY2562175 increases the interaction between FXR and steroid receptor coactivator 1 (SRC-1) with an EC50 value of 121 nM in a cell-free assay. It reduces plasma triglyceride and total cholesterol levels in LDL receptor-null mice (ED50s = 3.4 and 2 mg/kg, respectively). LY2562175 also decreases plasma LDL and increases HDL levels in Zucker diabetic fatty (ZDF) rats when administered at doses of 3, 10, and 30 mg/kg for nine days.

Uses

LY2562175, is a potent and selective FXR agonist with an EC50 of 193 nM.

Upstream product

• 1103500-82-8 6-{4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]piperidin-1-yl}-1-methyl-1H-indole-3-carboxylic acid methyl ester 
• 1103500-88-4 tert-butyl 6-(4-{[3-(2,6-dichlorophenyl)-5-cyclopropylisoxazol-4-yl]methoxy}piperidin-1-yl)-1-methylindole-3-carboxylate 
• 946426-94-4 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole 
• 1296211-56-7 4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]piperidine-1-carboxylic acid tert-butyl ester 
• 101774-27-0 6-bromo-1H-indole-3-carboxylic acid 
• 868656-97-7 6-bromo-1H-indole-3-carboxylic acid methyl ester 
• 946426-89-7 4-(hydroxymethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 
• 946426-88-6 5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-carboxylic acid methyl ester 
• 771-50-6 1H-indole-3-carboxylic acid 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 1103501-11-6 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-((piperidin-4-yloxy)methyl)isoxazole 

Relevant articles and documents

Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

The farnesoid X receptor (FXR) is a member of the "metabolic" subfamily of nuclear receptors. Several FXR agonists have been reported in the literature to have profound effects on plasma lipids in animal models. To discover novel and effective therapies for dyslipidemia and atherosclerosis, we have developed a series of potent FXR agonists that robustly lower plasma LDL and vLDL in LDLr-/- mice. To this end the novel piperidinylisoxazole system LY2562175 was discovered. This molecule is a potent and selective FXR agonist in vitro and has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. The preclinical ADME properties of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced to the clinic for evaluation in humans. The synthesis and biological profile of this molecule is discussed.